Honokiol in glioblastoma recurrence: a case report

Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ce, Cai, Zehao, Huang, Yue, Liu, Xinrui, Liu, Xing, Chen, Feng, Li, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324972/
https://www.ncbi.nlm.nih.gov/pubmed/37426439
http://dx.doi.org/10.3389/fneur.2023.1172860
_version_ 1785069213953556480
author Wang, Ce
Cai, Zehao
Huang, Yue
Liu, Xinrui
Liu, Xing
Chen, Feng
Li, Wenbin
author_facet Wang, Ce
Cai, Zehao
Huang, Yue
Liu, Xinrui
Liu, Xing
Chen, Feng
Li, Wenbin
author_sort Wang, Ce
collection PubMed
description Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes. We report an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma.
format Online
Article
Text
id pubmed-10324972
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103249722023-07-07 Honokiol in glioblastoma recurrence: a case report Wang, Ce Cai, Zehao Huang, Yue Liu, Xinrui Liu, Xing Chen, Feng Li, Wenbin Front Neurol Neurology Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes. We report an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10324972/ /pubmed/37426439 http://dx.doi.org/10.3389/fneur.2023.1172860 Text en Copyright © 2023 Wang, Cai, Huang, Liu, Liu, Chen and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Wang, Ce
Cai, Zehao
Huang, Yue
Liu, Xinrui
Liu, Xing
Chen, Feng
Li, Wenbin
Honokiol in glioblastoma recurrence: a case report
title Honokiol in glioblastoma recurrence: a case report
title_full Honokiol in glioblastoma recurrence: a case report
title_fullStr Honokiol in glioblastoma recurrence: a case report
title_full_unstemmed Honokiol in glioblastoma recurrence: a case report
title_short Honokiol in glioblastoma recurrence: a case report
title_sort honokiol in glioblastoma recurrence: a case report
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324972/
https://www.ncbi.nlm.nih.gov/pubmed/37426439
http://dx.doi.org/10.3389/fneur.2023.1172860
work_keys_str_mv AT wangce honokiolinglioblastomarecurrenceacasereport
AT caizehao honokiolinglioblastomarecurrenceacasereport
AT huangyue honokiolinglioblastomarecurrenceacasereport
AT liuxinrui honokiolinglioblastomarecurrenceacasereport
AT liuxing honokiolinglioblastomarecurrenceacasereport
AT chenfeng honokiolinglioblastomarecurrenceacasereport
AT liwenbin honokiolinglioblastomarecurrenceacasereport

Ejemplares similares